Tech Company Financing Transactions
Amylyx Pharmaceuticals Funding Round
On 7/2/2020, Amylyx Pharmaceuticals raised $30 million in Series B funding from Morningside Group and private investors.
Transaction Overview
Company Name
Announced On
7/2/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Morningside Group (Lead Investor) (Isaac Cheng)
Proceeds Purpose
This funding will help us continue to press ahead as rapidly as possible because every day counts for patients with ALS, Alzheimer's and other neurological conditions.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
43 Thorndike St.
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Undisclosed
Website
Email Address
Overview
Amylyx is an IND-enabling stage biopharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases. We have a highly creative and motivated team focused on streamlined clinical development and drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Cohen
Chief Executive Officer
Justin Klee
Chief Financial Officer
James Frates
Chief Medical Officer
Patrick Yeramian
Chief Scientific Officer
Kent Leslie
VP - Bus. Development
Margaret Olinger
VP - Human Resources
Debra Canner
Browse more venture capital transactions:
Prev: 7/2/2020: BioDirection venture capital transaction
Next: 7/2/2020: Bolt Biotherapeutics venture capital transaction
Share this article
About Database of VC Transactions
We record every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs